Mariana Malheiro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mariana Malheiro has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Ana Martins
Medical Oncology, Hospital de São Francisco Xavier, Centro Hospitalar de Lisboa Ocidental, Lisbon, PRT
2 shared publications Ana-Cristina Albuquerque
Medical Oncology Department, Setúbal Hospital Centre, 2910-446 Setúbal, Portugal
1 shared publicationAna-Lucia Costa
Oncology Division, Santa Maria Hospital, Lisboa Norte Hospital Centre (CHLN), 1649-028 Lisbon, Portugal
1 shared publication- André Ferreira
Medical Oncology, Hospital de São Francisco Xavier, Centro Hospitalar de Lisboa Ocidental, Lisbon, PRT
1 shared publication - António Araújo
University of Porto
1 shared publication CARTAGO Study Group
1 shared publication
Latest Publications
- Open Access
- 9 January 2026
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 39 (2) , 149-157
Recomendações para a Abordagem do Tromboembolismo Venoso no Doente Oncológico em Fim de Vida: Consenso Nacional
O tromboembolismo venoso é uma complicação frequente em doentes oncológicos, sobretudo em fases avançadas, nas quais a presença de doença metastática pode aumentar o risco de trombose em cerca de 20 vezes relativamente aos estádios iniciais, sendo esse risco ainda mais acentuado nos doentes em fim de vida. Apesar da elevada prevalência, persistem lacunas significativas na evidência que orienta a sua gestão nesta fase da doença. A abordagem do tromboembolismo venoso nesta população representa um desafio terapêutico, dada a elevada taxa de recorrência trombótica e de complicações hemorrágicas. Adicionalmente, o diagnóstico é dificultado tanto pela inespecificidade dos sintomas como pela necessidade de evitar exames invasivos ou onerosos, que possam comprometer o conforto do doente. Este manuscrito, desenvolvido em colaboração entre o Grupo de Estudos de Cancro e Trombose e a Associação Portuguesa de Cuidados Paliativos, revê os principais desafios clínicos e éticos associados ao diagnóstico, tratamento e profilaxia do tromboembolismo venoso nesta população, com o intuito de apoiar a prática médica em decisões muitas vezes complexas. As recomendações aqui propostas baseiam-se na melhor evidência disponível, complementada pela experiência clínica dos autores e por uma reflexão ética centrada no doente. São apresentados critérios para orientar i) a decisão de iniciar, manter ou suspender anticoagulação; ii) o papel da imagiologia neste contexto; iii) as indicações para a tromboprofilaxia. Com esta síntese, pretende-se contribuir para uma prática mais informada e consistente, com foco na qualidade de vida e dignidade do doente, reforçando a qualidade dos cuidados prestados e promovendo a sua aplicação transversal nos diferentes contextos assistenciais.
- 9 January 2026
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 39 (2) , 149-157
Open AccessRecomendações para a Abordagem do Tromboembolismo Venoso no Doente Oncológico em Fim de Vida: Consenso Nacional
O tromboembolismo venoso é uma complicação frequente em doentes oncológicos, sobretudo em fases avançadas, nas quais a presença de doença metastática pode aumentar o risco de trombose em cerca de 20 vezes relativamente aos estádios iniciais, sendo esse risco ainda mais acentuado nos doentes em fim de vida. Apesar da elevada prevalência, persistem lacunas significativas na evidência que orienta a sua gestão nesta fase da doença. A abordagem do tromboembolismo venoso nesta população representa um desafio terapêutico, dada a elevada taxa de recorrência trombótica e de complicações hemorrágicas. Adicionalmente, o diagnóstico é dificultado tanto pela inespecificidade dos sintomas como pela necessidade de evitar exames invasivos ou onerosos, que possam comprometer o conforto do doente. Este manuscrito, desenvolvido em colaboração entre o Grupo de Estudos de Cancro e Trombose e a Associação Portuguesa de Cuidados Paliativos, revê os principais desafios clínicos e éticos associados ao diagnóstico, tratamento e profilaxia do tromboembolismo venoso nesta população, com o intuito de apoiar a prática médica em decisões muitas vezes complexas. As recomendações aqui propostas baseiam-se na melhor evidência disponível, complementada pela experiência clínica dos autores e por uma reflexão ética centrada no doente. São apresentados critérios para orientar i) a decisão de iniciar, manter ou suspender anticoagulação; ii) o papel da imagiologia neste contexto; iii) as indicações para a tromboprofilaxia. Com esta síntese, pretende-se contribuir para uma prática mais informada e consistente, com foco na qualidade de vida e dignidade do doente, reforçando a qualidade dos cuidados prestados e promovendo a sua aplicação transversal nos diferentes contextos assistenciais.
- Open Access
- 2 December 2024
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 30 (8)
Characterization of thrombosis risk in ambulatory patients with cancer: results of the observational, prospective, multicenter CARTAGO study
Background: Venous thromboembolism (VTE) is one of the leading causes of death in patients with cancer. Currently, there is a need to develop an easily applicable risk model that can identify patients who will benefit from receiving primary thromboprophylaxis to reduce the incidence of VTE. Patients and methods: This was a non-interventional, multicenter, observational, prospective study carried out in 62 Oncology and Hematology services in Spain and Portugal between January 2018 and December 2019. The main objective of the CARTAGO study was to develop a predictive model within a competitive risk framework to assess the risk of VTE in patients with cancer undergoing chemotherapy, biological, or hormonal treatment. Results: A total of 1596 patients were analyzed. VTE events occurred in 124 (8%) during the 6-month follow-up period (42% of deep vein thrombosis [DVT], 48% of pulmonary embolism [PE], and 10% of both DVT and PE). Four variables were selected for the multivariate predictive model to determine the risk of VTE (tumor type, D-dimer, compression of a vessel by the tumor, and leukocyte count). The 4 variables were associated with an increased risk of VTE (C-statistic, 0.646 [95%CI, 0.620-0.673]). The most significant variables in the internal validation with bootstrapping were the “very high risk” tumors (hazard ratio [HR] 2.032; 95%CI, 1.287-3.211). Conclusion: The CARTAGO model predicts the VTE risk in patients with cancer receiving anticancer therapy in an outpatient setting. This model can easily aid in identifying ambulatory patients who would probably benefit from primary thromboprophylaxis.
- 2 December 2024
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 30 (8)
Open AccessCharacterization of thrombosis risk in ambulatory patients with cancer: results of the observational, prospective, multicenter CARTAGO study
Background: Venous thromboembolism (VTE) is one of the leading causes of death in patients with cancer. Currently, there is a need to develop an easily applicable risk model that can identify patients who will benefit from receiving primary thromboprophylaxis to reduce the incidence of VTE. Patients and methods: This was a non-interventional, multicenter, observational, prospective study carried out in 62 Oncology and Hematology services in Spain and Portugal between January 2018 and December 2019. The main objective of the CARTAGO study was to develop a predictive model within a competitive risk framework to assess the risk of VTE in patients with cancer undergoing chemotherapy, biological, or hormonal treatment. Results: A total of 1596 patients were analyzed. VTE events occurred in 124 (8%) during the 6-month follow-up period (42% of deep vein thrombosis [DVT], 48% of pulmonary embolism [PE], and 10% of both DVT and PE). Four variables were selected for the multivariate predictive model to determine the risk of VTE (tumor type, D-dimer, compression of a vessel by the tumor, and leukocyte count). The 4 variables were associated with an increased risk of VTE (C-statistic, 0.646 [95%CI, 0.620-0.673]). The most significant variables in the internal validation with bootstrapping were the “very high risk” tumors (hazard ratio [HR] 2.032; 95%CI, 1.287-3.211). Conclusion: The CARTAGO model predicts the VTE risk in patients with cancer receiving anticancer therapy in an outpatient setting. This model can easily aid in identifying ambulatory patients who would probably benefit from primary thromboprophylaxis.
- Open Access
- 16 January 2022
- Published by Springer Nature in Cureus
- Vol. 14 (1) , e21282
Cutaneous and Cerebral Metastases From Primary Peritoneal Clear Cell Carcinoma
Peritoneal tumors are very uncommon and among them, primary peritoneal clear cell carcinoma is extremely rare and often misdiagnosed as others subtypes. There are only 13 cases of primary peritoneal clear cell carcinoma previously reported in the literature and there are no reports about cutaneous metastasis in this setting and only brain metastases were described to be associated with other primary peritoneal carcinoma subtypes. More information about this topic is needed and so we are presenting a new case of primary peritoneal clear cell carcinoma with cutaneous and cerebral metastases in a 34-year-old female.
- 16 January 2022
- Published by Springer Nature in Cureus
- Vol. 14 (1) , e21282
Open AccessCutaneous and Cerebral Metastases From Primary Peritoneal Clear Cell Carcinoma
Peritoneal tumors are very uncommon and among them, primary peritoneal clear cell carcinoma is extremely rare and often misdiagnosed as others subtypes. There are only 13 cases of primary peritoneal clear cell carcinoma previously reported in the literature and there are no reports about cutaneous metastasis in this setting and only brain metastases were described to be associated with other primary peritoneal carcinoma subtypes. More information about this topic is needed and so we are presenting a new case of primary peritoneal clear cell carcinoma with cutaneous and cerebral metastases in a 34-year-old female.
- Open Access
- 20 August 2020
- Published by Springer Nature in BMC Urology
- Vol. 20 (1) , 1-7
Clinical implications of the American Joint Committee on Cancer (AJCC) 8th edition update in seminoma pT1 subclassification
Background: Seminoma accounts for 30–50% of testicular germ cell tumors (TGCT)—the most common solid malignancy in men aged 15–35 years. The American Joint Committee on Cancer (AJCC) 8th edition (2018) created the subclassifications pT1a (tumor size < 3 cm) and pT1b (≥ 3 cm), despite not being universally recognized. Rete testis invasion (RTI) and tumor size > 4 cm are considered features associated with a higher recurrence risk, but not formally used for staging. The authors propose further understanding the subclassification’s potential impact in clinical practice, by summarizing current evidence and reviewing clinical cases in their institutions. Methods: All consecutive cases of seminoma stage I, pT1 treated in two institutions between January 2005 and December 2016 were included. Clinical data were retrieved, and variables were analyzed using SPSS. Relevant literature on the topic was reviewed. Results: Seminoma pT1 was identified in 58 patients. By using newly AJCC criteria, 29 (50%) would have been staged as pT1a and 29 (50%) pT1b. Median age at diagnosis was similar (33 in pT1a vs 32 in pT1b). Median follow-up time 5.8 years. Almost half (45%) of pT1b patients had a tumor size < 4 cm. The majority of either pT1a or pT1b were treated with chemotherapy or radiotherapy, reflecting more intensive approaches in the past. Three retroperitoneal recurrences were recorded (two in pT1a, one in pT1b, all under surveillance protocol); no deaths occurred. RTI and extensive necrosis (EN) were associated with pT1b (P < 0.0001 and P = 0.023, respectively), known adverse biological features. Conclusions: In our population, the exploratory analysis of the newly created AJCC criteria showed no significant difference in recurrence or death, although pT1b was associated with adverse biomarkers, such as RTI and EN, but its clinical relevance remains incompletely understood. Our results confirm an excellent prognosis, regardless of subcategorization, thus a larger population and a longer follow-up time are needed to understand prospectively the impact of the recently updated criteria. We would recommend using the latest AJCC staging system, although the individual risk of relapse, long-term toxicities and patient preferences should be taken into account when considering surveillance or active treatment adjuvant options.
- 20 August 2020
- Published by Springer Nature in BMC Urology
- Vol. 20 (1) , 1-7
Open AccessClinical implications of the American Joint Committee on Cancer (AJCC) 8th edition update in seminoma pT1 subclassification
Background: Seminoma accounts for 30–50% of testicular germ cell tumors (TGCT)—the most common solid malignancy in men aged 15–35 years. The American Joint Committee on Cancer (AJCC) 8th edition (2018) created the subclassifications pT1a (tumor size < 3 cm) and pT1b (≥ 3 cm), despite not being universally recognized. Rete testis invasion (RTI) and tumor size > 4 cm are considered features associated with a higher recurrence risk, but not formally used for staging. The authors propose further understanding the subclassification’s potential impact in clinical practice, by summarizing current evidence and reviewing clinical cases in their institutions. Methods: All consecutive cases of seminoma stage I, pT1 treated in two institutions between January 2005 and December 2016 were included. Clinical data were retrieved, and variables were analyzed using SPSS. Relevant literature on the topic was reviewed. Results: Seminoma pT1 was identified in 58 patients. By using newly AJCC criteria, 29 (50%) would have been staged as pT1a and 29 (50%) pT1b. Median age at diagnosis was similar (33 in pT1a vs 32 in pT1b). Median follow-up time 5.8 years. Almost half (45%) of pT1b patients had a tumor size < 4 cm. The majority of either pT1a or pT1b were treated with chemotherapy or radiotherapy, reflecting more intensive approaches in the past. Three retroperitoneal recurrences were recorded (two in pT1a, one in pT1b, all under surveillance protocol); no deaths occurred. RTI and extensive necrosis (EN) were associated with pT1b (P < 0.0001 and P = 0.023, respectively), known adverse biological features. Conclusions: In our population, the exploratory analysis of the newly created AJCC criteria showed no significant difference in recurrence or death, although pT1b was associated with adverse biomarkers, such as RTI and EN, but its clinical relevance remains incompletely understood. Our results confirm an excellent prognosis, regardless of subcategorization, thus a larger population and a longer follow-up time are needed to understand prospectively the impact of the recently updated criteria. We would recommend using the latest AJCC staging system, although the individual risk of relapse, long-term toxicities and patient preferences should be taken into account when considering surveillance or active treatment adjuvant options.